IDEXX Laboratories (IDXX) moved back into focus after its Q2 2026 earnings report, as strong revenue and EPS figures, combined with higher full-year guidance, drew fresh attention from investors.

Despite the upbeat Q2 2026 report, IDEXX Laboratories' short term share price momentum has been weak, with the stock down about 4% over the past month and about 19% year to date. The 3 year total shareholder return of roughly 7% contrasts with a decline over 5 years, suggesting longer term investors have seen modest gains overall, but more recent sentiment has cooled even as earnings and guidance have drawn renewed interest.

Power up your research beyond IDEXX Laboratories by comparing how other high quality healthcare and diagnostics stocks have held up this year using our curated 76 resilient stocks with low risk scores.

Bulls point to IDEXX Laboratories' strong Q2 delivery and higher 2026 guidance, while bears focus on a double digit share price pullback. Which side does the current valuation argument appear to support as investors reassess the stock?

Most Popular Narrative: 23.1% Undervalued

The most followed narrative currently places IDEXX Laboratories' fair value at $709.14, compared with a last close of $545.08. This frames the valuation debate after Q2 2026.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits meaningfully above today's price? The narrative focuses on recurring diagnostics, higher margins, and a richer earnings profile built over several years. The key factor is the compounding of those high margin revenue streams. The details are contained within the model.

Result: Fair Value of $709.14 (UNDERVALUED)

However, IDEXX Laboratories still faces real pressure if veterinary visit volumes stay weak or if instrument placements slow, which could weigh on recurring diagnostics revenue and margins.

Another View on IDEXX Laboratories Using Market Multiples

The earlier fair value narrative for IDEXX Laboratories suggests upside, but the current P/E of 37.7x tells a different story. It is higher than both the estimated fair ratio of 29.2x and the US Medical Equipment industry average of 26.6x, which points to valuation risk if expectations slip. Which signal do you weigh more heavily?

Next Steps

With mixed signals on valuation and sentiment around IDEXX Laboratories, it makes sense to review the data for yourself and move quickly to form a view. To see both the potential upside and the areas that concern investors, check out the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond IDEXX Laboratories?

If you are reassessing IDEXX Laboratories today, it makes sense to keep fresh ideas on your radar using broader stock screens that match your style and risk tolerance.

• Target potential value opportunities by scanning companies that currently look mispriced on quality and fundamentals through the 46 high quality undervalued stocks.
• Lock in reliable income ideas by reviewing companies that appear in the 12 dividend fortresses and focus on stronger yield profiles with resilient cash flows.
• Strengthen your core holdings by searching for businesses with cleaner financials using the list of solid balance sheet and fundamentals (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.